AGT dsRNA Composition for Angiotensinogen Expression Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antihypertensive drugs often fail to control hypertension in more than two-thirds of patients, necessitating multiple medications and causing side effects, highlighting the need for alternative and combination therapies to manage angiotensinogen-related diseases.
Innovation Solution
Development of double-stranded ribonucleic acid (dsRNA) agents targeting angiotensinogen (AGT) expression, comprising specific sense and antisense strands with regions of complementarity to inhibit AGT mRNA, optionally with modified nucleotides and targeting ligands, to reduce AGT protein levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antihypertensive drugs are used to treat hypertension, then blood pressure can be reduced, but more than two-thirds of patients fail to achieve adequate control and experience side effects from multiple medications
Solution Approach 1:
The patent extracts and targets the root cause of hypertension by specifically inhibiting angiotensinogen (AGT) expression using dsRNA agents. Instead of using multiple drugs to address different symptoms, the invention directly targets the upstream AGT protein that drives the entire renin-angiotensin-aldosterone system, thereby achieving better control with a single targeted therapy and reducing side effects from polypharmacy
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific blood pressure reduction to specific AGT expression inhibition. By using dsRNA agents that specifically bind to and degrade AGT mRNA, the invention achieves precise molecular-level targeting, improving efficacy through mechanism-based therapy rather than symptom-based treatment
2Reliability
If multiple antihypertensive medications are prescribed to achieve blood pressure control, then hypertension management coverage increases, but patient compliance decreases and side effects increase
Solution Approach 1:
The patent extracts the core pathological driver (AGT) from the complex hypertension pathway and targets it specifically. This single targeted intervention replaces the need for multiple medications, simplifying the treatment regimen to one agent that addresses the root cause, thereby improving patient compliance while maintaining comprehensive hypertension control
Solution Approach 2:
The dsRNA agent targeting AGT performs multiple therapeutic functions simultaneously: it reduces AGT protein levels, inhibits angiotensin II formation, and blocks downstream pathological effects. This multi-functional single-agent therapy replaces multiple single-function drugs, improving compliance without sacrificing control coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents effectively inhibit AGT expression, potentially reducing hypertension and associated conditions by decreasing blood pressure and AGT levels, offering a more targeted and less invasive treatment approach.
Implementation Method 1
nucleotide positions 2 to 18 in the antisense strand including a region of complementarity to an AGT RNA transcript
Implementation Method 2
double-stranded ribonucleic acid (dsRNA) agents targeting angiotensinogen (AGT) expression
Data Source
AI summary
Provided are a composition and method for inhibiting angiotensinogen (AGT) protein expression. Specifically, provided are a composition and method capable of being used for reducing AGT gene expression and treating AGT-related diseases and disorders. Provided are an AGT dsRNA reagent capable of being used for reducing AGT expression in a cell and an object, an AGT antisense polynucleotide reagent, a composition containing the AGT dsRNA reagent, and a composition containing the AGT antisense polynucleotide reagent.